

Nancy J Devlin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3143066/publications.pdf>

Version: 2024-02-01

114
papers

8,429
citations

101543

36
h-index

49909

87
g-index

119
all docs

119
docs citations

119
times ranked

10841
citing authors

#	ARTICLE	IF	CITATIONS
1	Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics (United Kingdom), 2004, 13, 437-452.	1.7	863
2	EQ-5D and the EuroQol Group: Past, Present and Future. Applied Health Economics and Health Policy, 2017, 15, 127-137.	2.1	684
3	Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics (United Kingdom), 2004, 13, 437-452.	1.7	609
4	Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Quality of Life Research, 2010, 19, 875-886.	3.1	574
5	Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment, 2015, 19, 1-504.	2.8	536
6	Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 2016, 19, 1-13.	0.3	437
7	A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol. Value in Health, 2014, 17, 445-453.	0.3	341
8	Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Quality of Life Research, 2010, 19, 887-897.	3.1	325
9	Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 2016, 19, 125-137.	0.3	320
10	Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Economics (United Kingdom), 2010, 19, 886-905.	1.7	206
11	The development of new research methods for the valuation of EQ-5D-5L. European Journal of Health Economics, 2013, 14, 1-3.	2.8	205
12	Assessing the performance of the EQ-VAS in the NHS PROMs programme. Quality of Life Research, 2014, 23, 977-989.	3.1	192
13	The Influence of Cost-Effectiveness and Other Factors on Nice Decisions. Health Economics (United Kingdom), 2004, 13, 437-452.	1.7	166
14	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncology, The, 2016, 17, e510-e514.	10.7	158
15	Is there a case for using visual analogue scale valuations in cost-utility analysis?. Health Economics (United Kingdom), 2006, 15, 653-664.	1.7	155
16	Methods for Analysing and Reporting EQ-5D Data. , 2020, , .		125
17	Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?. Health and Quality of Life Outcomes, 2015, 13, 171.	2.4	124
18	“Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making. Health Policy, 2006, 77, 352-367.	3.0	112

#	ARTICLE	IF	CITATIONS
19	A uniform time trade off method for states better and worse than dead: feasibility study of the "lead time" approach. Health Economics (United Kingdom), 2011, 20, 348-361.	1.7	111
20	Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?. Pharmacoeconomics, 2020, 38, 325-340.	3.3	86
21	Operationalizing Value-Based Pricing of Medicines. Pharmacoeconomics, 2013, 31, 1-10.	3.3	84
22	International Valuation Protocol for the EQ-5D-Y-3L. Pharmacoeconomics, 2020, 38, 653-663.	3.3	84
23	Logical inconsistencies in survey respondents' health state valuations - a methodological challenge for estimating social tariffs. Health Economics (United Kingdom), 2003, 12, 529-544.	1.7	81
24	Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?. Medical Decision Making, 2010, 30, 556-565.	2.4	76
25	Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. Pharmacoeconomics, 2018, 36, 699-713.	3.3	74
26	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. Value in Health, 2018, 21, 1291-1298.	0.3	70
27	Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. Pharmacoeconomics, 2018, 36, 1345-1353.	3.3	67
28	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncology, The, 2018, 19, e459-e469.	10.7	66
29	New methods for modelling EQ-5D-5L value sets: An application to English data. Health Economics (United Kingdom), 2018, 27, 23-38.	1.7	61
30	Protocols for Time Tradeoff Valuations of Health States Worse than Dead: A Literature Review. Medical Decision Making, 2010, 30, 610-619.	2.4	56
31	A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO. Health Economics (United) Tj ETQq _{1,1} 0.784314 rgBT ₅₁	1.7	51
32	PRIORITIZING PATIENTS FOR ELECTIVE SURGERY. International Journal of Technology Assessment in Health Care, 2003, 19, 91-105.	0.5	47
33	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. Health Technology Assessment, 2014, 18, vii-xxvi, 1-191.	2.8	47
34	A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). Pharmacoeconomics, 2015, 33, 867-877.	3.3	45
35	Cultural Values: Can They Explain Differences in Health Utilities between Countries?. Medical Decision Making, 2019, 39, 605-616.	2.4	42
36	Hospital Variation in Patient-Reported Outcomes at the Level of EQ-5D Dimensions. Medical Decision Making, 2013, 33, 804-818.	2.4	39

#	ARTICLE	IF	CITATIONS
37	Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. <i>Medical Care</i> , 2014, 52, 935-943.	2.4	38
38	QALYs as a measure of value in cancer. <i>Journal of Cancer Policy</i> , 2017, 11, 19-25.	1.4	38
39	An exploration of methods for obtaining 0â€™=â€™dead anchors for latent scale EQ-5D-Y values. <i>European Journal of Health Economics</i> , 2020, 21, 1091-1103.	2.8	36
40	Putting patient-reported outcomes on the â€™Big Data Road Mapâ€™. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 299-303.	2.0	34
41	Lead versus lag-time trade-off variants: does it make any difference?. <i>European Journal of Health Economics</i> , 2013, 14, 25-31.	2.8	33
42	What Determines the Shape of an EQ-5D Index Distribution?. <i>Medical Decision Making</i> , 2016, 36, 941-951.	2.4	33
43	Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?. <i>Value in Health</i> , 2019, 22, 45-49.	0.3	31
44	A new tool for creating personal and social EQ-5D-5L value sets, including valuing â€™deadâ€™. <i>Social Science and Medicine</i> , 2020, 246, 112707.	3.8	31
45	Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?. <i>Medical Decision Making</i> , 2021, 41, 584-596.	2.4	30
46	3L, 5L, What the L? A NICE Conundrum. <i>Pharmacoeconomics</i> , 2018, 36, 637-640.	3.3	28
47	Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures. <i>Pharmacoeconomics</i> , 2022, 40, 379-431.	3.3	28
48	A Study of the Relationship between Health and Subjective Well-Being in Parkinsonâ€™s Disease Patients. <i>Value in Health</i> , 2014, 17, 372-379.	0.3	27
49	An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. <i>Quality of Life Research</i> , 2017, 26, 2067-2078.	3.1	27
50	Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 130.	2.4	27
51	Comparison of the Underlying Constructs of the EQ-5D and Oxford Hip Score: Implications for Mapping. <i>Value in Health</i> , 2011, 14, 884-891.	0.3	26
52	A new method for valuing health: directly eliciting personal utility functions. <i>European Journal of Health Economics</i> , 2019, 20, 257-270.	2.8	26
53	Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. <i>European Journal of Health Economics</i> , 2013, 14, 43-51.	2.8	25
54	The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework. <i>European Journal of Health Economics</i> , 2013, 14, 15-24.	2.8	24

#	ARTICLE	IF	CITATIONS
55	One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands. <i>European Journal of Health Economics</i> , 2013, 14, 65-73.	2.8	23
56	INTER-PROVIDER COMPARISON OF PATIENT-REPORTED OUTCOMES: DEVELOPING AN ADJUSTMENT TO ACCOUNT FOR DIFFERENCES IN PATIENT CASE MIX. <i>Health Economics (United Kingdom)</i> , 2015, 24, 41-54.	1.7	22
57	Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). <i>PharmacoEconomics - Open</i> , 2018, 2, 153-163.	1.8	22
58	An Analysis of NICE's "Restricted" (or "Optimized") Decisions. <i>Pharmacoeconomics</i> , 2010, 28, 987-993.	2.1	21
59	An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate Health State Values in the United Arab Emirates. <i>Value in Health Regional Issues</i> , 2015, 7, 34-41.	1.2	20
60	Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data. <i>Health Services and Delivery Research</i> , 2014, 2, 1-90.	1.4	20
61	Association between market concentration of hospitals and patient health gain following hip replacement surgery. <i>Journal of Health Services Research and Policy</i> , 2015, 20, 11-17.	1.7	19
62	Opportunity costs and local health service spending decisions: a qualitative study from Wales. <i>BMC Health Services Research</i> , 2016, 16, 103.	2.2	19
63	Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. <i>Value in Health</i> , 2016, 19, 255-266.	0.3	19
64	The effect of religion on the perception of health states among adults in the United Arab Emirates: a qualitative study. <i>BMJ Open</i> , 2017, 7, e016969.	1.9	19
65	Local health care expenditure plans and their opportunity costs. <i>Health Policy</i> , 2015, 119, 1237-1244.	3.0	16
66	A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 469-477.	2.1	16
67	The EQ-5D-5L Value Set for England: Response to the "Quality Assurance". <i>Value in Health</i> , 2020, 23, 649-655.	0.3	16
68	An Introduction to EQ-5D Instruments and Their Applications. , 2020, , 1-22.		16
69	A Comparison of PROPr and EQ-5D-5L Value Sets. <i>Pharmacoeconomics</i> , 2022, 40, 297-307.	3.3	14
70	Analysis of EQ-5D Profiles. , 2020, , 23-49.		13
71	Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. <i>Vaccine</i> , 2022, 40, 4008-4016.	3.8	12
72	EQ-5D-5L Health-State Values for the Mexican Population. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 905-914.	2.1	11

#	ARTICLE	IF	CITATIONS
73	The relationship between physical and mental health multimorbidity and children's health-related quality of life. <i>Quality of Life Research</i> , 2022, 31, 2119-2131.	3.1	11
74	Distribution of the EQ-5D-5L Profiles and Values in Three Patient Groups. <i>Value in Health</i> , 2019, 22, 355-361.	0.3	10
75	The Influence of Cost-Effectiveness and Other Factors on NICE Decisions. <i>SSRN Electronic Journal</i> , 2013, , .	0.4	9
76	Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review. <i>Quality of Life Research</i> , 2022, 31, 79-89.	3.1	9
77	Psychometric Performance of HRQoL Measures: An Australian Paediatric Multi-Instrument Comparison Study Protocol (P-MIC). <i>Children</i> , 2021, 8, 714.	1.5	9
78	Analysis of EQ-5D Values. , 2020, , 61-86.		9
79	Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. <i>European Journal of Health Economics</i> , 2017, 18, 967-977.	2.8	8
80	Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial. <i>Patient</i> , 2017, 10, 677-686.	2.7	8
81	Using a modified Delphi methodology to gain consensus on the use of dressings in chronic wounds management. <i>Journal of Wound Care</i> , 2018, 27, 156-165.	1.2	8
82	Valuing EQ-5D-5L health states "in context" using a discrete choice experiment. <i>European Journal of Health Economics</i> , 2018, 19, 595-605.	2.8	8
83	Euthanasia, religiosity and the valuation of health states: results from an Irish EQ5D5L valuation study and their implications for anchor values. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 152.	2.4	8
84	Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments. <i>European Journal of Health Economics</i> , 2019, 20, 99-105.	2.8	8
85	Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1950-1977.	1.7	8
86	Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 635-644.	2.1	8
87	Sugammadex, neostigmine and postoperative pulmonary complications: an international randomised feasibility and pilot trial. <i>Pilot and Feasibility Studies</i> , 2021, 7, 200.	1.2	8
88	How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents. <i>Pharmacoeconomics</i> , 2022, 40, 157-182.	3.3	8
89	Longitudinal study of patients' health-related quality of life using EQ-5D-3L in 11 Swedish National Quality Registers. <i>BMJ Open</i> , 2022, 12, e048176.	1.9	8
90	The Development of the EQ-5D-5L and its Value Sets. , 2022, , 1-12.		8

#	ARTICLE	IF	CITATIONS
91	Valuing Child Health Isnâ€™t Childâ€™s Play. <i>Value in Health</i> , 2022, 25, 1087-1089.	0.3	8
92	The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states. <i>Wellcome Open Research</i> , 0, 7, 14.	1.8	7
93	UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 363-370.	0.5	6
94	A note on the relationship between age and health-related quality of life assessment. <i>Quality of Life Research</i> , 2019, 28, 1201-1205.	3.1	6
95	Giving a Voice to Marginalised Groups for Health Care Decision Making. <i>Patient</i> , 2021, 14, 5-10.	2.7	6
96	Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 22.	1.9	6
97	Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>Quality of Life Research</i> , 2017, 26, 1187-1195.	3.1	5
98	Health today versus health tomorrow: does Australia really care less about its future health than other countries do?. <i>Australian Health Review</i> , 2020, 44, 337.	1.1	5
99	Preference Elicitation Techniques Used in Valuing Childrenâ€™s Health-Related Quality-of-Life: A Systematic Review. <i>Pharmacoeconomics</i> , 2022, 40, 663-698.	3.3	5
100	Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5L valuation study in Ireland. <i>Health Policy</i> , 2020, 124, 639-646.	3.0	4
101	Variations in Patientsâ€™ Overall Assessment of Their Health Across and Within Disease Groups Using the EQ-5D Questionnaire: Protocol for a Longitudinal Study in the Swedish National Quality Registers. <i>JMIR Research Protocols</i> , 2021, 10, e27669.	1.0	4
102	The Economics of a â€˜Liberatedâ€™ NHS. <i>Pharmacoeconomics</i> , 2010, 28, 1075-1078.	3.3	3
103	Assessing Patient-Reported Outcomes in Pediatric Populations With Vaccine-Preventable Infectious Diseases: A Systematic Review of the Literature (the PROCHID Study). <i>Value in Health</i> , 2016, 19, 109-119.	0.3	3
104	Assessing the Performance of the EQ-VAS in the NHS PROMs Programme. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
105	Guidance to Users of EQ-5D-5L Value Sets. , 2022, , 213-233.		3
106	What Determines the Shape of an EQ-5D Index Distribution?. <i>SSRN Electronic Journal</i> , 2014, , .	0.4	2
107	Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
108	A Comparison of Alternative Variants of the Lead and Lag Time TTO. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2

#	ARTICLE	IF	CITATIONS
109	An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib. <i>Value in Health</i> , 2022, , .	0.3	2
110	International guidelines for self-report and proxy completion of paediatric health-related quality of life measures: a protocol for a systematic review. <i>BMJ Open</i> , 2021, 11, e052049.	1.9	2
111	An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
112	Analysis of EQ VAS Data. , 2020, , 51-59.		1
113	All Male Panels and Other Diversity Considerations for ISPOR. <i>PharmacoEconomics - Open</i> , 2019, 3, 423-426.	1.8	0
114	Time to Tweak the TTO: But How?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0